In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit;Actividad in vitro de terapia combinada con colistina frente a Pseudomonas aeruginosa aisladas en Unidad de Cuidados Intensivos

Revista Espanola de Quimioterapia

Volumn 21, Issue 3, 2008, Pages 189-193

  López Fabal, Fatima ^a   Culebras, E ^a   Bonilla, I ^a   Gomez M ^a   Picazo, J J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Colistin; P. aeruginosa; Rep PCR; Synergistic activity

Indexed keywords

AZITHROMYCIN; COLISTIN; DOXYCYCLINE; PRIMER RNA; REPETITIVE DNA; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COLISTIN; DOXYCYCLINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; RIFAMPIN;

EID: 55049106416     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005;11(Suppl. 4):17-32.
2. Sánchez A, Salso S, Culebras E, Picazo JJ. Carbapenem resistance determined by metalloenzymes in clinical isolates of Pseudomonas aeruginosa. Rev Esp Quimioter 2004:17:336-40.
3. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13:560-78.
4. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006;27:224-8.
5. Tascini C, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004;16:282-7.
6. National Committee for Clinical Laboratory Standards. En: Wayne PA, editor. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically standard M7-A6. NCCLS, 2003; p. 1.
7. Syrmis MW, O'Carroll MR, Sloots TP, Coulter C, Wainwright CE, Bell SC, et al. Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays. J Med Microbiol 2004;53:1089-96.
8. Dawson SL, Fry JC, Dancer BN. A comparative evaluation of five typing techniques for determining the diversity of fluorescent pseudomonas. J Microbiol Methods 2002;50:9-22.
9. Coll P, Coque MT, Dominguez MA, Vázquez J, Vila J. Procedimientos en Microbiologia Clinica. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clinica: métodos moleculares de tipificación epidemiológica en Bacteriología, 2005.
10. Marqués MB, Brookings ES, Moser SA, Sonke PB, Waites KB. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997; 41:881-5.
11. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
12. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003;15:235-8.
13. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:3136-46.